Related Experiment Videos
Monosialoganglioside in subarachnoid hemorrhage.
I Papo1, A Benedetti, A Carteri
1Neurosurgical Department, Ospedale Le Torrette, Ancona, Italy.
Stroke
|January 1, 1991
Summary
Monosialoganglioside treatment improved consciousness in patients with subarachnoid hemorrhage. This neuroprotection therapy showed significant benefits in reducing brain edema and enhancing neuronal recovery over 21 days.
Area of Science:
- Neurosurgery
- Neurology
- Pharmacology
Background:
- Subarachnoid hemorrhage (SAH) often leads to disturbance of consciousness.
- Aneurysm rupture is a common cause of SAH.
- Effective treatments are needed to improve outcomes in SAH patients.
Purpose of the Study:
- To evaluate the efficacy of monosialoganglioside in patients with disturbance of consciousness post-SAH.
- To assess the impact of monosialoganglioside on brain edema and neuronal protection.
Main Methods:
- A double-blind, placebo-controlled study involving 119 patients with SAH.
- Patients received either monosialoganglioside or placebo.
- Glasgow Coma Scale scores were used to assess consciousness at baseline and on days 7, 14, and 21.
Main Results:
- Both groups showed improvement, but the monosialoganglioside group exhibited a greater rate and degree of improvement.
- Statistically significant differences in consciousness improvement were observed on day 14 (p=0.04) and day 21 (p=0.02).
Conclusions:
- Monosialoganglioside treatment appears to reduce brain edema following subarachnoid hemorrhage.
- The findings support the hypothesis that monosialoganglioside offers nonspecific neuronal membrane protection.
- This suggests a potential therapeutic benefit for monosialoganglioside in managing SAH-induced consciousness disturbances.